Vical makes two appointments to board
This article was originally published in Scrip
Vical, a company developing biopharmaceutical products based on DNA delivery technologies, has appointed Richard Beleson and Stephen Sherwin to its board of directors. Mr Beleson retired as senior vice-president of Capital Group Companies in 2010, where previously he was an equity investment analyst and institutional investor focused on the biotechnology and pharmaceutical industries. Mr Sherwin is a clinical professor of medicine at the University of California, San Francisco. He is co-founder and chair of the board of directors at Ceregene and a member of the boards of Biogen Idec, BioSante Pharmaceuticals, Neurocrine Biosciences, Rigel Pharmaceuticals, and Verastem. He is also a member of the board and chair Emeritus of the Biotechnology Industry Organization.